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Cientı´ficas), Madrid, SpainABSTRACT Biological fluids contain a very high total concentration of macromolecules that leads to volume exclusion by one
molecule to another. Theory and experiment have shown that this condition, termed macromolecular crowding, can have signif-
icant effects on molecular recognition. However, the influence of molecular crowding on recognition events involving virus
particles, and their inhibition by antiviral compounds, is virtually unexplored. Among these processes, capsid self-assembly
during viral morphogenesis and capsid-cell receptor recognition during virus entry into cells are receiving increasing attention
as targets for the development of new antiviral drugs. In this study, we have analyzed the effect of macromolecular crowding
on the inhibition of these two processes by peptides. Macromolecular crowding led to a significant reduction in the inhibitory
activity of: 1), a capsid-binding peptide and a small capsid protein domain that interfere with assembly of the human immuno-
deficiency virus capsid, and 2), a RGD-containing peptide able to block the interaction between foot-and-mouth disease virus
and receptor molecules on the host cell membrane (in this case, the effect was dependent on the conditions used). The results,
discussed in the light of macromolecular crowding theory, are relevant for a quantitative understanding of molecular recognition
processes during virus infection and its inhibition.INTRODUCTIONThe total concentration of macromolecules in intracellular
compartments and extracellular fluids is extremely high
(ranging from ~80 mg/mL in blood plasma to ~300 mg/mL
in bacterial cells). Such conditions lead to excluded volume
effects arising from the mutual impenetrability of soluble
macromolecules, a situation known as macromolecular
crowding (1–5). In a crowded solution, the reactivity of
a given solute is determined by the number of solute mole-
cules per unit of available (not total) volume. Thus, in
a molecularly crowded medium, the thermodynamic activity
(i.e., effective concentration) will be higher than in a dilute
solution by a factor that corresponds to the activity coeffi-
cient of that solute.
Crowding is a nonspecific force that favors reactions
leading to a reduction in the total excluded volume, such
as the formation of soluble macromolecular complexes or
insoluble aggregates, folding of proteins, and the binding
of macromolecules to surface sites. Many of the effects
predicted by macromolecular crowding theory have been
observed experimentally using a large variety of systems
involving proteins and/or other cellular components (e.g.,
(1–16)). The magnitude of the crowding effect is highly
dependent on the sizes and shapes of crowding species
and dilute macromolecular species. For example, macromo-
lecular crowding in volume-occupied media will increase
the thermodynamic activity of large and/or elongated
macromolecules relative to that of small, compact solutes;Submitted September 9, 2010, and accepted for publication December 15,
2010.
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binding of large and/or elongated ligands to a receptor rela-
tive to that of small, compact ligands (2).
During the life cycle of viruses, most reactions in which
viral macromolecules or the viral particles themselves
participate also occur in molecularly crowded environ-
ments, either intracellular or extracellular. To what extent
macromolecular crowding could have an influence on the
different specific recognition steps of the viral life cycle
has remained, to our knowledge, a virtually unexplored
question, despite its relevance for a better understanding
of virus biology and the fight against viral disease. In
a previous study, we used an in vitro system to show that
addition of macromolecular crowding agents induced the
efficient assembly of the human immunodeficiency virus
type 1 (HIV-1) capsid in close to physiological conditions
(10). In this study, our goal has been to experimentally
analyze whether macromolecular crowding could have an
influence on the inhibition by different compounds of essen-
tial steps of the viral cycle that involve virus particles.
Most licensed or candidate antiviral drugs are small
molecules that act by binding a viral or cellular macromol-
ecule or macromolecular complex, such as a virus capsid,
and inhibiting its function (17–20). In particular, two very
promising antiviral strategies that are receiving increasing
attention are
1. The inhibition of virus assembly.
2. The inhibition of virus-host cell recognition or virus entry.
For example, several experimental inhibitors of HIV-1
capsid assembly have been described (21–25). In addition,doi: 10.1016/j.bpj.2010.12.3714
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entry have been recently licensed for chemotherapy against
HIV-1 infection (20), and others are in different stages of
development and/or trials. Some of these antiviral
compounds are small peptides (e.g., (20,22–24,26–32).
Both virus self-assembly and virus-cell receptor recogni-
tion do occur in macromolecularly crowded environments
in vivo. Because of their outstanding interest as new targets
for antiviral therapy, in this work we have focused on these
two crucial steps of the viral cycle. To this aim, we have
used specific, in vitro simplified models of these viral
processes that are well established in our laboratory.
As a model for the inhibition of virus capsid self-
assembly, we chose HIV-1. During HIV morphogenesis,
a molecular reorganization process occurs where the mature
capsid is assembled from hundreds of copies of its mono-
meric component, the capsid protein CA (see recent reviews
in (33,34)). The CA protein is composed of two domains.
The smaller, C-terminal domain (CTD) is responsible for
CA dimerization and, in its isolated form, is able to effi-
ciently inhibit the in vitro assembly of the HIV-1 capsid
(35,36). Other compounds such as small organic molecules
(21), lipids (37), dendrimers (25), and peptides ((22,23)
and Rebeca Bocanegra, Jose´ Luis Neira, and Mauricio G.
Mateu, unpublished results) are also able to inhibit this
process. A small peptide (CAI) that was identified by
screening a combinatorial library of dodecapeptides binds
the CTD and is able to impair the polymerization of CA
into capsids by inducing a conformational distortion of
CTD and/or sterically impairing self-association of CA
(22,38,39).
A substantially modified, conformationally restricted
peptide variant of CAI has been shown to penetrate suscep-
tible cells and inhibit HIV-1 infection ex vivo (23). The inhi-
bition of HIV-1 capsid assembly by CTD or CAI is
a consequence of their binding to capsid-building blocks
and growing capsid particles, thus interfering with CA-CA
recognition (22,35,36). According to favored models (40),
those building blocks include not only CA dimers, but
also preassembled, higher-order oligomers of considerably
larger size than CA, CTD, and CAI.
As a model for the inhibition of virus-host cell receptor
recognition we chose foot-and-mouth disease virus
(FMDV), the causative agent of one of the most economi-
cally important animal diseases worldwide (reviewed in
(41,42)). Infection by FMDV involves the attachment of
the virion to integrin receptors on the host cell membrane,
through a RGD-containing protein loop (the G-H loop of
protein VP1) on the virus capsid (reviewed in (43)). This
loop is structurally free-standing and mobile, and partici-
pates in few or no contacts with other capsid regions (44).
Accordingly, the VP1 G-H loop of FMDV can be mimicked
by small RGD-containing peptides (43,45–53). In partic-
ular, synthetic peptides that reproduce the sequence of
the central 15–20 amino acids of this viral loop are able toefficiently inhibit the infectivity of serotype C FMDV to
BHK-21 cells, by competitively impairing the attachment
of the virus to the cell receptors (49,51). The inhibition of
FMDV infectivity by RGD peptides is due to a steric
blockade of the recognition by the virion of integrin recep-
tors on the surface of the host cells (43,47–49).
Using these two well-characterized in vitro or ex vivo
systems, we have quantitatively compared the inhibitory
activity of the above-mentioned molecules on either
assembly of the HIV capsid or cell binding and infectivity
of the FMDV virion, in the absence or presence of high
concentrations of a macromolecular crowding agent. The
conceptual framework and the implications for the inhibi-
tion of crucial steps of the viral cycle are discussed.MATERIALS AND METHODS
Virus and cell lines
FMDV C-S8c1 is a plaque-purified virus clone (54). The BHK-21c2 cell
line used derives from a cell clone obtained by limiting dilution (55). Cells
were cultivated in Dulbecco’s modified Eagle’s medium containing nones-
sential amino acids, gentamycin, and buthyl parahydroxybenzoate, and
supplemented with 5% fetal bovine serum (56).Synthetic peptides
Solid-phase synthesized and purified peptides with an amydated C-terminus
were provided by Prof. D. Andreu (Universitat Pompeu Fabra, Barcelona,
Spain). For the inhibition of HIV-1 capsid assembly, the CAI peptide
(ITFEDLLDYYGP) (22) was used. An inactive peptide (KAFSPEVIPM
FSALSEGAT), which represents a segment of the CTD sequence of CA
from HIV-1, was used as a negative control.
For the inhibition of FMDV-cell receptor recognition, two overlapping
synthetic peptides that represent the central amino-acid sequence of the
G-H loop in VP1 of FMDV C-S8c1 were used: peptide A15 (VP1 residues
136–150: YTASARGDLAHLTTT) and peptide A19 (VP1 residues 138–
156: ASARGDLAHLTTTHARHLP) (45,50). Peptide A15RGE, a variant
A15 peptide with an inactivating, Asp-to-Glu substitution at the RGD motif
(YTASARGELAHLTTT), was used as a negative control. The peptides
were dissolved in complete phosphate-buffered saline (PBS). Peptide
A19 coupled to keyhole limpet hemocyanin (A19-KLH) (46) was also
used. The A19-KLH conjugate solution was dialyzed immediately before
use to eliminate any free A19 peptide and other low-molecular-weight
contaminants.Purification of HIV-1 capsid protein CA
and its C-terminal domain
CA of HIV-1 (strain BH10) and its CTD were purified, and their purity and
concentration determined, essentially as described previously (10,57).In vitro assembly of the HIV-1 capsid
Assembly reactions (10) were carried out in 50 mM sodium phosphate
buffer pH ¼ 7.4, 2.25 M NaCl and 46 mM CA in the absence or presence
of 100 g/L Ficoll 70 or 50 g/L Dextran T40. A volume of CA solution
at the appropriate concentration in 50 mM sodium phosphate buffer was
introduced into a spectrophotometer cuvette (10 mm  2 mm internal
section), and the assembly reaction was triggered by adding a solutionBiophysical Journal 100(3) 738–746
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or 90 g/L Dextran T40 to get the final concentrations desired for each
component in a final volume of 500 mL, followed by rapid mixing.
For inhibition assays, CAwas mixed with the appropriate amount of CTD
or CAI to get the desired inhibitor/CAmolar ratio, and incubated for 30 min
before triggering the reaction. The time-dependent increase in the optical
density at 350 nm as a measure of the light scattered by the assembled parti-
cles was monitored at 25C, using a model No. UV-1603 spectrophotometer
(Shimadzu, Columbia, MD) with data points collected every 6 s. Traces of
the variation in the turbidity were analyzed as described previously (10).
The time-dependent increase in optical density fitted very well the empir-
ical Hill function,
OD ¼ ODf ððt=t50Þn=ð1 þ ðt=t50ÞnÞ;
where OD is the optical density at incubation time t, ODf is the optical
density at infinite time, t50 is the time at which the OD is equal to one-half
the ODf, and n is a cooperativity parameter (9).
The polymerization rate kp in each tested condition was determined from
the slope of the approximately linear portion of the curve. The ratio kpi/kp0
between the polymerization rate in the presence or absence of the inhibitor
yielded the reduction in the polymerization rate at each concentration of
inhibitor tested. The relative amount of capsid formed was estimated
from the OD corresponding to the plateau of the turbidity curves
(10,35,36). The ratio ODi/OD0 between the plateau OD in the presence
or absence of the inhibitor yielded the reduction in the amount of capsid
formed at each concentration of inhibitor tested.Purification of the FMDV virion
FMD virions were purified as previously described (58) with some modifi-
cations. Briefly, BHK-21c2 cell monolayers in 12 B175 flasks were infected
with FMDV C-S8c1 at a multiplicity of infection of 3. After complete
cytopathic effect, the medium and remaining cells were recovered, and
the cells were lysed by freezing and thawing, followed by the addition of
2% chloroform. The cell debris were removed by centrifugation, and the
supernatant was loaded on a 20% sucrose cushion in TNE buffer (10 mM
Tris-HCl pH ¼ 7.5, 100 mM NaCl, 1 mM EDTA), and centrifuged at
25,000 rpm for 2.5 h at 4C in a AH627 rotor (Sorvall, Newtown, CT).
The pellet was thoroughly resuspended in ~0.6 mLTNE and the suspension
centrifuged through a 7.5–30% sucrose gradient in TNE at 37,000 rpm for
1 h at 4C in a SW40 rotor (Beckman Coulter, Brea, CA). A quantity of
0.5 mL fractions was recovered, and those containing virions were pooled
and dialyzed against incomplete PBS at 4C. The purity of the preparation
was assessed by SDS-Urea-PAGE.FMDV inactivation
Purified FMDV virions were inactivated essentially as described previously
(59–61). Briefly, 2.4 mL of a virus suspension in incomplete PBS were
mixed with 1.2 mL of inactivating buffer (0.3 M Tris-HCl pH ¼ 8.5,
1.5 M NH4Cl), filtered through a cellulose acetate membrane (0.45 mM
pore; Pall Life Sciences, East Hills, NY), and incubated for 4 h at 37C.
Then, the suspension was dialyzed against incomplete PBS. Complete
inactivation was assessed by titration in standard plaque assays.Cell toxicity assays
A colorimetric method (CellTiter 96 AQueous One Solution Cell Prolifer-
ation Assay; Promega, Fitchburg, WI) was used according to the instruc-
tions provided by the manufacturer. Briefly, near-confluent BHK-21 cell
monolayers in 96-well plates were washed with incomplete PBS (Ca2þ
and Mg2þ-free), and incubated during 90 min at room temperature with
increasing concentrations (0–200 g/L) of Ficoll 70. The cells were thenBiophysical Journal 100(3) 738–746washed with DMEM and incubated for 90 min at 37C with MTS ([3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium]), and the absorbance at 490 nm was determined in a
microplate reader.Inhibition of FMDV infectivity
The general outline of the assay was as described previously (51), but the
conditions were appropriately varied. A quantity of 80% confluent BHK-
21 cell monolayers in P60 petri dishes was washed with DMEM and incu-
bated for 45 min at room temperature with a volume of 180 mL of either
complete PBS, with or without Ficoll 70 (as a negative control), or with
increasing concentrations (0.1–100 mM) of A15 or A19 peptides or
A19-KLH conjugate diluted in complete PBS, with or without Ficoll 70.
Except where stated otherwise, a final concentration of 100 g/L Ficoll 70
was used. Then, 20 mL of a virus suspension were added. The virus suspen-
sion contained 100 plaque-forming units of FMDV C-S8c1 (supernatant of
infected cultures) in complete PBS at two physical particle/infectious
particle ratios. In the experiments we used either 105 or 109 physical virus
particles and ~106 cells. If we assume a somewhat conservative figure of
103 av-containing integrin receptor molecules able to bind FMDV per
cell (62), the virus/receptor ratios used were 104 and 1.
The higher ratio was achieved by mixing the appropriate amounts of
a suspension of infectious viral particles and a suspension of viral particles
that had been completely inactivated as described above. In this way, the
percent inhibition at different virus/receptor ratios could be obtained in
the same type of experiment, and directly compared. The only relevant
difference between the two conditions is the total number of viral particles
used due to the different physical/infectious viral particle ratio; noninfec-
tious and infectious viral particles show no differences in binding to the
cell receptors. After the virus was added to the cell monolayers, these
were incubated for 45 min at room temperature, washed with DMEM,
covered with a semisolid agar overlay, and further incubated for 24 h at
37C. The monolayers were fixed and stained, and the viral plaques
counted. The inhibitory activity was compared by using the IC50 value,
defined as the concentration of inhibitor needed to reduce the number of
viral plaques to 50% of the initial value.RESULTS
Effects of macromolecular crowding on the
inhibition of the in vitro assembly of the
HIV-1 capsid by the capsid-binding CAI peptide
and the CTD
The first model system used in this study involves a compe-
tition for binding to growing HIV-1 capsidlike particles
between the capsid building blocks (CA dimers and other
small oligomers (40)) and the inhibitor molecule, either
the isolated CTD or the CAI peptide. The inhibitory
activity of both molecules was compared in the absence or
presence of a high concentration of an inert macromolecule,
Ficoll 70.
The inhibitory effects on HIV-1 capsid assembly of the
isolated CTD domain or CAI at different inhibitor/CAmolar
ratios are shown in Figs. 1 and 2. In the absence of crowd-
ing, addition of increasing amounts of free CTD (Fig. 1 a)
or CAI (Fig. 1 c) led to decreasing CA polymerization rates
(kp) and decreasing amounts of assembled capsids (indi-
cated by the OD plateau in the polymerization curves).
For example, at a CTD/CA molar ratio of 2, the kpi/kp0 ratio
FIGURE 1 Effect of macromolecular crowding on the inhibition of the
in vitro assembly of the HIV-1 capsid. Reaction kinetics of CA polymeriza-
tion followed by measuring the optical density at 350 nm as a function of
time after triggering the reaction are shown. (a and b) Inhibition by the
CTD domain in the absence (a) or presence (b) of 100 g/L Ficoll 70 as
an inert macromolecular crowding agent. (c and d) Inhibition by the CAI
peptide in the absence (c) or presence (d) of 100 g/L Ficoll 70. (e and f)
Inhibition by the CAI peptide in the absence (e) or presence (f) of 50 g/L
Dextran T40. The CA (monomer) concentration used was 46 mM. In
each panel, the inhibitor/CA molar ratios used (from 0 to 2) are indicated.
In each panel, a representative experiment is shown. Average and standard
deviation values from the processed results of several comparable experi-
ments are shown in Fig. 2.
FIGURE 2 Inhibition of the CA polymerization rate by CTD and CAI.
Each bar represents as a percentage the kpi/kp0 ratio, i.e., the ratio between
the polymerization rate obtained in the presence of inhibitor relative to that
obtained in its absence (bars labeled –I) for each inhibitor/CA molar ratio
tested (from 0.1 to 0.5 for CAI or from 0.2 to 2 for CTD), either in the
absence (open bars) or in the presence (solid bars) of 100 g/L Ficoll 70
(all solid bars but the one labeled with an asterisk) or 50 g/L Dextran
T40 (solid bar labeled with an asterisk) as an inert macromolecular crowd-
ing agent. Each value represents the average of two, three, or four measure-
ments obtained in independent experiments. The standard deviations are
indicated. Experimental conditions were as described in the legend for
Fig. 1.
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fivefold reduction of the polymerization rate and a twofold
reduction in the total amount of capsid formed, relative to
absence of inhibitor) (Fig. 1 a and Fig. 2). At a CAI/CA
molar ratio as low as 0.5, both the kpi/kp0 ratio and the
ODi/OD0 ratio were <0.1 (corresponding to 10-fold reduc-
tion in both polymerization rate and total amount of capsid
formed, relative to absence of inhibitor) (Fig. 1 c and Fig. 2).
Thus both the CTD and, even more so, the CAI peptide
(which inhibits polymerization by a different mechanism
than CTD), behaved in these experiments as effective inhib-
itors of HIV-1 capsid assembly in the absence of crowding.
An inactive peptide used as a negative control had no inhib-
itory effect at all on CA polymerization (data not shown).
Addition of 100 g/L Ficoll 70 as a macromolecular crow-
der had little effect on the total amount of capsid formed in
the absence of inhibitor, but dramatically increased kp, bothin the absence or presence of increasing amounts of CTD
(Fig. 1 b) or CAI (Fig. 1 d). Remarkably, the inhibitory
activities of CTD and CAI were substantially reduced in
the presence of macromolecular crowding, relative to its
absence. On average, in the presence of either inhibitor,
and at different inhibitor/CA molar ratios, addition of the
crowding agent roughly doubled the kpi/kp0 ratio (Fig. 2),
and led also to a large increase in the ODi/OD0 ratio
(Fig. 1). For example, at a CTD/CA molar ratio of 2, the
ODi/OD0 ratio increased from ~0.5 in the absence of crow-
der to ~0.9 when the crowding agent was added, corre-
sponding to a reduction of the inhibition by CTD from
50% to only 10%. Even more dramatically, at a CAI/CA
molar ratio of 0.5, the ODi/OD0 ratio increased from ~0.1
in the absence of crowder to ~0.7 when the crowder was
present, corresponding to a reduction of the inhibition by
CAI from 90% to 30%.
Similar results were obtained when the inhibition of
HIV-1 capsid assembly by CAI was analyzed in the pres-
ence of other inert crowding agents including dextran T40
(Fig. 1, e and f) or the protein bovine serum albumin (results
not shown). For example, at a CAI/CA molar ratio of 0.2,
the ODi/OD0 ratio increased from ~0.5 in the absence of
crowder to ~1.0 when the crowder was present, correspond-
ing to a reduction of the inhibition by CAI from 50% to
close to 0%. As expected, the reduced inhibition under
macromolecular crowding conditions was not dependent
on the molecular nature of the crowding agent used.
To summarize this part of the study, we have used a high
concentration of macromolecular crowding agents to mimicBiophysical Journal 100(3) 738–746
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prevail in the budding HIV-1 virion where the mature capsid
is assembled in vivo (10,34). The results show that macro-
molecular crowding can lead to a significant reduction in
the inhibitory activity of both the isolated CTD and the
CTD-binding CAI peptide on the in vitro assembly of the
HIV-1 capsid.FIGURE 4 Inhibition of FMDV infectivity by synthetic peptides. (a and
b) Inhibition in the absence of crowding agent by free peptides A19 (trian-
gles), A15 (circles), or A15RGE (squares) (a) or by A19-KLH conjugate (b).
The data points for A19, A15, A15RGE, and A19-KLH, respectively, repre-
sent the average of nine, four, four, or seven measurements obtained in
three, two, two, or three independent experiments. The standard deviations
are indicated. (c and d) Comparison of the inhibition of FMDV infectivity
by free peptide A19 at two different virus/receptor ratios in the absence
(open bars) or presence (solid bars) of Ficoll 70 as a crowding agent.
The virus/receptor ratio in panel d is 104-fold higher than that in panel c.
The values in panels c and d, respectively, represent the average of nine
or four measurements obtained in three or two independent experiments.
The standard deviations are indicated.Effect of macromolecular crowding on the
inhibition of FMDV-cell recognition and virus
infectivity by RGD-containing peptides
Evaluation of the toxicity of the macromolecular crowding
agent used
We first determined the maximum concentration of Ficoll
70 that could be used in the infectivity assays without a toxic
effect on the target cells. No significant cytotoxic effect was
found in repeated experiments, even at a concentration of
200 g/L Ficoll (Fig. 3). Thus, for the virus inhibition assays
we generally chose a Ficoll concentration of 100 g/L, as
this proved to be clearly nontoxic, and is enough to mimic
the macromolecular crowding conditions exerted in physio-
logical fluids.
Evaluation of the inhibitory activity on FMDV infectivity
of RGD-containing peptides
Next we determined the concentrations of the A15 and A19
peptides (either in free form or conjugated to a large protein)
that were needed, in the absence of an external macromolec-
ular crowding agent, to achieve efficient inhibition of cell
attachment and infectivity of FMDV C-S8c1 (Fig. 4,
a and b). The variant peptide A15RGE (with the RGD motif
inactivated) was used as a negative control. Peptide A15RGEFIGURE 3 Evaluation of the cytotoxic effect of Ficoll 70 on cultured
BHK21c2 cells. The values of absorbance, directly proportional to cell
viability, are the average of six measurements. The standard deviations
are indicated.
Biophysical Journal 100(3) 738–746showed, as expected, no detectable inhibitory effect even at
a concentration of 100 mM. In contrast, both A19 and A15
peptides showed a strong inhibitory activity, yielded
a similar IC50 (~1–2 mM), and reached close to 100% inhi-
bition at a concentration of 100 mM (Fig. 4 a). The results
using a multivalent A19-KLH conjugate showed that the
peptide was about as active as a large protein conjugate
(IC50 ~1 mM peptide concentration; see Fig. 4 b) as it
was as a free peptide (Fig. 4 a). Remarkably, as the
peptide/KLH molar ratio in the conjugate is very high,
this latter result indicates that multivalency of a receptor-
binding motif per se may not necessarily lead to increased
activity in the recognition of its receptor on the surface
of host cells. From the above experiments, a range of
0.1 mM–100 mM peptide concentration (either free or
coupled to KLH) was chosen for the subsequent assays.
Evaluation of the effect of macromolecular crowding
on the inhibition of FMDV infectivity by peptides
After the appropriate concentrations of crowding agent
and RGD peptides had been determined, the effect of
Virus Inhibition in a Crowded Medium 743macromolecular crowding on the inhibition of FMDV
infectivity by the A19 peptide was investigated. The ratio
between the number of binding sites (FMDV receptors)
in the membrane of infection-susceptible cells and the
number of circulating viral particles may vary widely
both in natural and laboratory infections. Thus, we decided
to analyze the effects of macromolecular crowding at two
very different virus particle/receptor ratios, estimated to
be 104 and 1 (see Materials and Methods). The first ratio
would leave most cell receptors unoccupied by the virions,
while the second ratio would be closer to saturation of the
viral receptors by virions. The number of binding sites (cell
receptors) and other experimental conditions were kept
invariant.
The results of the comparison are shown in Fig. 4, c and d.
At the lower virus particle/receptor ratio tested, no signifi-
cant differences in the inhibitory activity of the free A19
peptide in the absence or presence of 100 g/L Ficoll 70
were found (Fig. 4 c). The same lack of effect of macromo-
lecular crowding conditions on the inhibitory activity was
observed for a shorter RGD peptide, A15, or for a very large
A19-KLH peptide conjugate (results not shown). In
contrast, at the higher virus particle/receptor ratio tested,
the inhibitory activity of the A19 peptide was significantly
reduced in the presence of macromolecular crowding, rela-
tive to its absence (Fig. 4 d). The decrease was substantial
only at low (up to 1 mM) peptide concentrations. However,
in this situation as much as a 20-fold higher peptide concen-
tration was needed to achieve in a crowded media (100 g/L
Ficoll 70) the same inhibitory effect observed in a dilute
solution.
To confirm that the reduced inhibitory activity of the
peptide at the higher virus/receptor ratio tested is due to
an effect of macromolecular crowding, we repeated the
experiment, but this time using different concentrations
of Ficoll 70 (0, 50, 100, and 200 g/L). As expected,
an inverse dependence on Ficoll concentration of the
inhibitory activity of the peptide was observed, both at
low (1 mM) and higher (10 mM) peptide concentrations.
For example, in the absence of Ficoll, a low concentration
of peptide (1 mM) reduced virus infectivity by ~25%.
Addition of 50 g/L Ficoll had no significant effect. At
100 g/L Ficoll, the inhibition was reduced to only ~5%;
at 200 g/L Ficoll, the inhibitory activity of the peptide
(at the same peptide concentration) was essentially
abolished.
To summarize this second part of the study, we have used
a high concentration of a macromolecular crowding agent to
approximate in vitro the macromolecular crowding condi-
tions that prevail in extracellular fluids where viruses bind
their cellular receptors. The results show that macromolec-
ular crowding, depending on the virus/cell receptor ratio,
can lead to a significant reduction on the inhibitory activity
of a RGD-containing peptide on FMD virus-host cell recog-
nition and virus infectivity.DISCUSSION
The two models we have used to study the inhibition by
small molecules of either capsid self-assembly or virus-
cell recognition basically involve:
1. A large target macromolecule or macromolecular
assembly (T), either the growing HIV-1 capsid or the in-
tegrin receptor on the host cell membrane.
2. A competition between an inhibitor peptide (I) of a rela-
tively small size (molecular weight of ~103–104), and
larger or much larger macromolecules (M), either the
CA building blocks that form by accretion capsidlike
particles, or FMD virions (molecular weight 8  106).
3. The conditional presence of an inert macromolecule (C).
The presence of C at very high concentrations allowed us
to achieve in vitro macromolecular crowding conditions
that resemble those in the physiological fluids where
assembly of the mature HIV-1 capsid (inside the budding
virion) or FMDV-cell recognition (the extracellular fluid
of certain tissues) occur in vivo.
Ficoll 70was chosen as amodel crowding agent because of
its low viscosity, a size comparable to those ofmany proteins,
and its low tendency to interact specificallywith other solutes
such as proteins (63). The Ficoll concentrations used in this
study would approximately correspond to the volume occu-
pancy estimated for extracellular conditions, or only some-
what lower than typical intracellular conditions. At these
concentrations, this compound adequately promotes
in vitro the crowded environment that in vivo originates
mainly from a heterogeneous mixture of proteins.
The use of a single inert crowding agent to approximately
mimic the volume occupancy due to complex mixtures of
macromolecules in biological fluids allows the assignment
of the observed effects to volume exclusion. This approach
avoids the complications due to additional effects that could
occur if complex macromolecular mixtures were used
instead (see, for example, (64)). Because of the above
reasons, Ficoll 70 is widely and extensively used by many
researchers as a chemically defined, inert agent that leads
to macromolecular crowding in simplified in vitro models.
The main result we obtained using either system (inhibi-
tion of capsid self-assembly or inhibition of virus-cell inter-
actions) is that macromolecular crowding can significantly
reduce the inhibitory effects of the antiviral peptides tested.
Volume exclusion theory may provide a simplified concep-
tual framework and a general thermodynamic explanation
for this experimental result: if the sizes of I (competitive
inhibitor) and M (competed macromolecule) are similar,
the inhibitory activity of I in a crowded solution would be
similar to that in a nonphysiological, diluted (ideal) solu-
tion. In contrast, if I is clearly smaller than M, the inhibitory
activity of I in crowded conditions would be significantly
reduced, relative to that in a dilute solution, as theoretically
justified by Minton (example I in (2)) and summarized next.Biophysical Journal 100(3) 738–746
744 Rinco´n et al.If M can bind T (target macromolecule) with an apparent
equilibrium association constant KMT, and I can bind T
with an apparent equilibrium association constant KIT, the
relationships between KMT or KIT and the corresponding
true equilibrium association constant KoMT or K
o
IT of the
reaction are
KMT ¼ KoMTgM;
KIT ¼ KoITgI;
where gM and gI, respectively, denote the thermodynamic
(chemical) activity coefficient of M and I. Then, the prefer-
ence ratio (P) of T for M, relative to I, will be
KMT=KIT ¼

KoMTgM

KoITgI
 ¼ P0ðgM=gIÞ;
where P0 is the preference ratio of T for M relative to I, in an
ideal solution (and thus, in the absence of crowding), where
gM¼ gI¼ 1. When an inert background species C is present
at high concentrations (acting as amacromolecular crowding
agent), the value of the activity coefficient gx will depend, in
part, on the size of the reactant X relative to the size of C
(Ficoll 70 is larger than the inhibitors I used in our study).
In addition, if I is smaller than M, as is the case in our two
models, gM will increase with the concentration of C faster
than gI because the available volume under these conditions
is lower for M than for I. Thus, gM/gI will be higher than
unity, and the value of P will be higher than P0.
In agreement with this theoretical prediction, it has been
very recently shown that small chemical ligands that bind
DNA G-quadruplexes, and thus inhibit telomerase activity,
were significantly less effective under macromolecular
crowding conditions (65). However, to our knowledge the
prediction that macromolecular crowding may generally
impair the inhibitory activity of small compounds (2),
despite its biological relevance, had not been tested to
date in any other cellular or viral system.
If the implicit assumptions and simplifications of the
above theoretical analysis apply to the complex experi-
mental models and under the conditions we have used, it
could be expected that the preference ratio for association
of the larger building blocks to the growing HIV-1 capsid,
relative to the association of the smaller inhibitor peptides
CAI and even CTD, would be higher in macromolecular
crowding conditions than in a dilute solution. Likewise,
the preference ratio for association of the large FMDV
virions to the cell receptors, relative to the association of
the smaller inhibitor peptide A19, would be higher in
macromolecular crowding conditions than in a dilute solu-
tion. For both viral models, the antiviral activity of the
peptide inhibitors is predicted to be reduced in the presence
of macromolecular crowding, and this is precisely what we
have experimentally observed in this study.
It must be noted, however, that the available theoretical
analysis (2) does not seem to provide an explanation on
why, in the case of the FMDV infection, the predicted effectBiophysical Journal 100(3) 738–746of crowding was indeed observed, but apparently vanished
at very low virus/receptor (V/R) ratios. We suggest that
this may be due to an opposing, specific effect occurring
in this complex system, but we are uncertain about its origin.
Complexities of this system include:
1. The virus, unlike the peptide, can recruit several receptor
molecules; its internalization may depend on the number
of receptors attached, which may be dependent in turn on
the V/R ratio.
2. FMDV is known to bind several different receptors with
high affinity, but the same may not hold true for the
peptide; multiple competing reactions could occur to
different extents at different V/R ratios.
3. Unproductive collision with receptors may conforma-
tionally alter the viral particles and its infectivity; the
collision frequency will depend on the V/R ratio.
4. The receptors were not in solution, but fixed to a cell
membrane (see (66) for an example regarding predic-
tions of macromolecular crowding theory on association
reactions at cellular membranes).
Because of these or other reasons, some of the simplifying
assumptions made by theory may have to be revised for
this complex system. However, it is important to note that
the theoretically predicted reduction in the inhibitory
activity of the peptides occurred under some conditions in
this system, and under any tested condition in the less
complex viral capsid assembly system also investigated in
this study.
It is also clear that the use of a single crowding agent
provides only a first approximation to experimentally study
some effects of high macromolecular concentrations. Bio-
logical environments are crowded but also heterogeneous
media, and volume exclusion will not be the only factor
affecting biochemical rates and equilibria. Further studies
will be needed to evaluate whether the observed volume
exclusion effects on virologically relevant macromolecular
reactions are compounded by other effects derived from
the presence of a complex mixture of macromolecules.
These considerations underscore the need for more quantita-
tive definitions of model systems and further theoretical
developments to achieve a better understanding of associa-
tion reactions in molecularly crowded environments.
The results obtained may also have practical implications
for the initial testing of small molecules aimed at inhibiting
virus assembly or virus-cell receptor recognition. The
inhibitory activity of candidate antiviral drugs in vivo may
be less than anticipated based on initial evaluation on test
tube or cell culture, if these experiments are carried out
in the absence of added macromolecular crowding agents.
For example, in typical HIV-1 capsid assembly in vitro
experiments, the total protein concentration is only
a few mg/mL at most. In ex vivo experiments directed to
assess the inhibition of virus-host cell recognition, the total
protein concentration in the cell culture medium, even if
Virus Inhibition in a Crowded Medium 745supplemented with as much as 5–10% fetal bovine serum,
will be ~1 mg/mL or less (67).
These total macromolecular concentrations correspond
to essentially diluted conditions, being approximately two-
orders-of-magnitude lower than those leading to macromo-
lecular crowding in vivo and to significant volume exclusion
effects. The use of high concentrations of a macromolecular
crowding agent in in vitro or ex vivo screening assays of
candidate antiviral compounds may contribute to a better
initial assessment of the inhibitory activity of these
compounds at the total macromolecular concentrations
they may encounter in vivo. This suggested approach could
contribute to a better selection of candidate compounds for
subsequent trials under more physiological conditions.CONCLUSIONS
The experimental results obtained in this study demonstrate
that macromolecular crowding can, at least under certain
conditions, substantially impair the inhibition by small
peptide molecules of capsid self-assembly or virus attach-
ment to receptors on the membrane of host cells. These
and other molecular recognition processes during the life
cycle of viruses involve competition between ligands of
widely different sizes and affinities, both outside and inside
the cell. Because macromolecular crowding is widespread
in both environments, volume exclusion effects may have
to be considered for a more quantitative understanding of
virus biology. In addition, most antiviral drugs in use for
inhibiting the activity of viral proteins, or being developed
for inhibiting virus assembly or virus-cell receptor recogni-
tion, are small organic compounds.
The results obtained with two very different virus model
systems indicate that the inhibitory activity of antiviral
drugs may be substantially tempered under macromolecular
crowding conditions such as those present in the organism.
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